Search

Displaying results 6011 - 6020 of 6830 in total
  1. Drug

    PF-04995274

    go.drugbank.com/drugs/DB12675
    Investigational

    Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

  2. Drug

    MT-0169

    go.drugbank.com/drugs/DB17430
    Investigational

    MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.

  3. Drug

    Inarigivir soproxil

    go.drugbank.com/drugs/DB15063
    Investigational

    Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic

  4. Drug

    Emodepside

    go.drugbank.com/drugs/DB11403
    InvestigationalVet approved

    Emodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively

  5. Drug

    GZ-389988

    go.drugbank.com/drugs/DB16056
    Investigational

    GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients

  6. Drug

    Moxazocine

    go.drugbank.com/drugs/DB20517
    Experimental

    The usage of the INN stem '-azocine' in the name indicates that Moxazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Moxazocine has a monoisotopic molecular weight of 287.19 Da.

  7. Drug

    Diminazene

    go.drugbank.com/drugs/DB03608
    Experimental

    This compound belongs to the phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent attached to a phenyl group.

  8. Drug

    Oxibendazole

    go.drugbank.com/drugs/DB04910
    ExperimentalVet approved

    Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.

  9. Drug

    Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

    go.drugbank.com/drugs/DB15813
    Investigational

    Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins … , modify artificial antigen presenting cells (aAPC), and activate T-cells.

  10. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to [DB00545] and [DB01400]. … It is an anticholinergic drug and long-acting reversible carbamate cholinesterase inhibitor that binds directly and competitively to the agonist binding sites of muscurinic receptors.